Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen.

Awital Bar Barroeta J Arnoud Marquart Kamran Bakhtiari Alexander Benjamin Meijer Rolf T Urbanus Joost C M Meijers

Published in: Journal of thrombosis and haemostasis : JTH (2022)

We have characterized a nanobody targeting the FXI apple 3 domain that elucidates the binding orientation of HK on FXI. Moreover, we have produced five nanobodies that can inhibit the FXI-FIX interaction.

Keyphrases

dna binding
binding protein
cancer therapy
single cell